Market Place
Sourcing Support
ViiV Health: Long-Acting Cabenuva Maintains HIV Control in Teens
26 Feb 2026 //
PHARMIWEB
CAN Community Health Hosts World AIDS Day Concert With Broadway
25 Nov 2025 //
BUSINESSWIRE
Viiv Healthcare Initiates `Risk To Reasons` Program for Women
28 Oct 2025 //
PHARMIWEB
GSK And Viiv Healthcare Pledge £6M To Boost Community Health
21 Oct 2025 //
PHARMIWEB
ViiV’s Dovato Matches Biktarvy Efficacy With Less Weight Gain
17 Oct 2025 //
BUSINESSWIRE
UK`s Recommends Use of GSK Unit`s HIV Prevention Drug
16 Oct 2025 //
REUTERS
Viiv Healthcare Presents Extensive Evidence At EACS & IDweek 2025
09 Oct 2025 //
BUSINESSWIRE
ViiV tops US patient groups` pharma reputation ranking
19 May 2025 //
FIERCE PHARMA
ViiV Healthcare Demonstrates Dovato Efficacy in Advanced HIV
11 Nov 2024 //
BUSINESSWIRE
ViiV Shows 99% Effectiveness For Apretude In HIV PrEP At IDWeek 2024
16 Oct 2024 //
BUSINESSWIRE
ViiV Healthcare To Triples Supply Of Long-Acting HIV PrEP
07 Oct 2024 //
BUSINESSWIRE
ViiV To Present Dovato Vs Biktarvy Trial Data At AIDS 2024
16 Jul 2024 //
INDIANPHARMAPOST
ViiV Healthcare To Present Dovato Vs Biktarvy Trial Data At AIDS 2024
15 Jul 2024 //
BUSINESSWIRE
UK MHRA grants Mkt approval for ViiV`s cabotegravir formulations prevent HIV-1
04 May 2024 //
PHARMABIZ
ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship
05 Mar 2024 //
BUSINESSWIRE
ViiV to present data for its next generation of ultra long-acting treatments for HIV
28 Feb 2024 //
BUSINESSWIRE
Comedians drive ViiV’s new ridesharing series about HIV prevention
12 Feb 2024 //
ENDPTS
ViiV Health announces new packaging option now available in the U.S. for Dovato
05 Feb 2024 //
BUSINESSWIRE
Colombia to seek compulsory license on ViiV`s dolutegravir
05 Oct 2023 //
FIERCE PHARMA
GSK`s ViiV to lean on HIV portfolio ahead of dolutegravir patent expiration
28 Sep 2023 //
ENDPTS
MSF calls out GSK`s ViiV for nondisclosure clauses in contract
17 Aug 2023 //
FIERCE PHARMA
GSK`s HIV prevention drug recommended for marketing approval in Europe
25 Jul 2023 //
PRESS RELEASE
ViiV grows HIV prevention campaign with influencers, including actor Taye Diggs
23 Jun 2023 //
ENDPTS
ViiV & Gilead hit impasse in HIV advertising dispute, case to feds for review
02 May 2023 //
ENDPTS
GSK`s ViiV says its long-acting HIV shot as effective as Gilead`s daily pill
23 Feb 2023 //
REUTERS
ViiV to present data for HIV treatment Cabenuva against oral Biktarvy at CROI
14 Feb 2023 //
PRESS RELEASE
ViiV works with private organizations in hopes of ending HIV
06 Dec 2022 //
FIERCEPHARMA
ViiV drives new corporate coalition including Uber aimed at ending HIV
01 Dec 2022 //
ENDPTS
ViiV Healthcare Unveils a New Global Study Revealing Three Quarters
30 Nov 2022 //
BUSINESSWIRE
ViiV takes to the couch for conversations HIV in its new ‘Science on the Sofa’
18 Nov 2022 //
ENDPTS
GSK’s ViiV Sues Exavir Over Licensing Pact on HIV-Drug Compounds
01 Nov 2022 //
BLOOMBERGLAW
EMA validates ViiV ’s MAA for cabotegravir long-acting inj for HIV prevention
29 Oct 2022 //
PHARMABIZ
ViiV Healthcare presents positive proof-of-concept findings for N6LS
25 Oct 2022 //
BUSINESSWIRE
ViiV Presents Showing Vocabria & Rekambys Can Be Implemented in EU Healthcare
24 Oct 2022 //
BUSINESSWIRE
ViiV Healthcare Announces Recipients of Largest Philanthropic Fund
07 Oct 2022 //
ACCESSWIRE
ViiV sets up monkeypox fund to deliver $500,000 in the US
12 Aug 2022 //
FIERCE PHARMA
GSK adds Queer Eye`s Karamo Brown to its list of celebs
10 Aug 2022 //
FIERCE PHARMA
ViiV strikes a deal to make its long-acting HIV injectable more accessible
01 Aug 2022 //
ENDPTS
ViiV Healthcare presents positive five-year data at AIDS 2022
29 Jul 2022 //
BUSINESSWIRE
GSK feeds HIV PrEP drug to patent pool amid US launch
29 Jul 2022 //
FIERCEPHARMA
ViiV Healthcare and Medicines Patent Pool Sign New Voluntary Licensing Agreement
28 Jul 2022 //
BUSINESSWIRE
ViiV wants HIV patients to ‘detect this’ for new Dovato ad
11 Jul 2022 //
FIERCEPHARMA
ViiV research strategy chief`s long quest to `cure` HIV
30 Jun 2022 //
FIERCEBIOTECH
ViiV, Gilead and Janssen notch top scores with HIV/AIDS groups
23 Jun 2022 //
FIERCEPHARMA
Altruistic initiatives aim to improve patient care in developing regions
07 Jun 2022 //
EUROPEANPHARMACEUTICALREVIEW
GSK`s ViiV adds an unexpected demographic to Dovato campaign
31 May 2022 //
FIERCEPHARMA
ViiV Healthcare announces marketing approval by Japan’s MHLW for Vocabria
31 May 2022 //
PRESS RELEASE
ViiV to make long-acting HIV prevention shot accessible in low income countries
28 May 2022 //
ENDPTS
GSK`s ViiV, Horizon and Pfizer tops with U.S. patient groups
13 May 2022 //
FIERCEPHARMA
FDA approves label update to ViiV’s long-acting HIV treatment
26 Apr 2022 //
OUTSOURCING-PHARMA
FDA Approves ViiV’s Triumeq PD for Children With HIV
01 Apr 2022 //
BLOOMBERG LAW
Complete Healthcare Management Releases Study on ViiV`s Dolutegravir Patent
30 Mar 2022 //
PRNEWSWIRE
ViiV wins another label update for long-acting HIV injectable Cabenuva
25 Mar 2022 //
ENDPTS
ViiV Healthcare’s readiness for voluntary licensing for cabotegravir in HIV
14 Mar 2022 //
PHARMABIZ
Viiv weighs in on FDA approval of long-acting HIV treatment
22 Feb 2022 //
OUTSOURCING-PHARMA
ViiV Healthcare to present new long-term findings from its innovative 2-drug
07 Feb 2022 //
BUSINESSWIRE
GlaxoSmithKline`s HIV drug Cabenuva scores FDA nod for 2-month dosing
02 Feb 2022 //
FIERCEPHARMA
GSK announces $1.25 bln settlement between ViiV Healthcare, Gilead
02 Feb 2022 //
REUTERS
ViiV’s new study finds HIV stigma and misunderstanding remain
06 Jan 2022 //
FIERCEPHARMA
